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T
he scientiﬁ  c enterprise reﬂ  ects 
the willingness of scientists 
to collaborate implicitly with 
people they don’t know personally: 
investigators routinely obtain 
antibodies, enzymes, sterile supplies, 
and other items from commercial 
suppliers without hardly blinking, and 
often without knowing anything about 
the companies other than what appears 
on the sales brochures. This system 
works because of basic warranties and 
expectations, as well as competition 
among companies to maintain high 
quality standards and easy, quick 
availability of specialized reagents. It 
is no exaggeration to say that vendors, 
as de facto scientiﬁ  c collaborators, 
are a major driving force in scientiﬁ  c 
productivity. 
In contrast, many scientists are far 
more reluctant to enter into explicit 
collaborations with other academic 
scientists, even those who are well 
respected and well established, unless 
they have a strong prior personal 
relationship with them. Why? 
There are many concerns that 
a scientist might have that could 
outweigh the potential advantages 
of collaboration with another 
academic. Unlike a commercial 
vendor, whose participation is passive 
and circumscribed, an academic 
collaborator is likely to argue 
passionately about the design of the 
experiments, may not agree with the 
underlying hypothesis, might engage in 
experiments that lack certain perceived 
controls or quality standards, or may 
simply lose momentum (e.g., if the 
lab loses grant support, or if a student 
in the lab leaves who was doing the 
experiments). Even after the basic 
experiments are ﬁ  nished, an academic 
collaborator might delay or even 
prevent publication by insisting on the 
need for further experiments, proper 
credit, a certain author name order, 
having intellectual property rights, 
submitting to a certain journal, and so 
on. Doing scientiﬁ  c research is a highly 
personal and subjective activity, so that 
it is difﬁ  cult to put two investigators 
together at random and expect 
them to see eye-to-eye. Also, each 
member of the collaboration is privy 
to valuable unpublished data, facts, 
ideas, and hypotheses that they are 
loathe to disclose to the other without 
good reason. Making a commitment 
to collaborate fully with another 
laboratory is far from a trivial decision.
Thus, collaborations tend to fall into 
one of two categories at opposite ends 
of the spectrum: on the one hand, the 
passive or one-sided vendor model, 
where a person supplies a reagent with 
minimal warranties and expectations; 
and on the other hand, the active 
collaborator model, where two or 
more investigators are fully engaged 
in a common pursuit with full sharing 
of ideas and credit (think Watson and 
Crick). This leaves an enormous set of 
potential opportunities in the middle, 
consisting of limited collaborations 
that could be mutually fruitful, but that 
often cannot get started or be sustained 
because of uncertainty and lack of 
trust. We suggest that it is possible 
to encourage more of these limited 
collaborations to proceed by providing 
a list of the key points to be considered 
at the onset of a collaboration.
What we have in mind is not 
along the lines of a legal contract; 
rather, we envision a set of voluntary 
“boilerplate” guidelines that two 
academic biomedical investigators, who 
are potential collaborators, can refer 
to as a reference point for negotiation. 
This would not threaten the current 
informal way that scientists tend to 
enter collaborations. Nor would the 
use of these guidelines incur any 
obligations on the universities or other 
institutions that employ the scientists 
involved. 
Although minimal guidelines for 
sharing of reagents and data have 
been widely discussed (e.g., [1–6]), to 
our knowledge, no one has explicitly 
enumerated the points of collaboration 
that should be negotiated between two 
academic biomedical investigators. 
Here, we propose a set of possible 
guidelines (Box 1). We conﬁ  ne the 
terms to collaborations between 
a supplier (of reagents, expertise, 
specialized equipment, data, methods, 
or computer code) and a receiver, 
who is often the initiator of the 
collaboration. However, the guidelines 
could apply to collaborations generally, 
regardless of the nature or direction 
of sharing involved, and regardless 
of whether the collaboration is 
formalized (e.g., as in a contract for 
services) or is pursued as an informal 
verbal agreement. As negotiations of 
intellectual property issues generally 
involve additional parties such as host 
institutions and funding agencies 
and are not solely under the control 
of the two collaborators, a detailed 
consideration of such issues falls 
beyond the scope of the present 
guidelines. 
These guidelines will be posted 
on the Science Commons Web site 
(http:⁄⁄science.creativecommons.org/) 
to provide a public forum encouraging 
scientiﬁ  c collaborators and others to 
provide feedback and suggestions, and 
allowing the guidelines to be modiﬁ  ed 
and extended over time.  
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1.  Sharing of reagents and data. 
• Minimal: Reagents or data will be provided that are 
essentially as described in published description, and Party 1 
warrants that these will be prepared, stored, and shipped in 
a manner that will preserve their value. Party 2 will pay the costs 
of shipping. If the reagent is not readily available in the supplier’s 
laboratory and there are no plans to prepare more, Party 2 may 
be asked to share reasonable costs of preparing the reagent 
for shipping. 
• Option  1: Party 1 will give all available information, based on 
unpublished results, to help the receiver save time and use the 
reagents in an optimal fashion. (For example, when supplying an 
antibody for immunohistochemistry, the supplier will suggest a 
proven range of dilutions, buffers, and ﬁ  xatives.) 
• Option  2: Both parties will describe the nature of unpublished 
information related to ongoing experiments in their respective 
laboratories, in sufﬁ  cient detail that the parties can decide whether 
it is mutually to their beneﬁ  t to share unpublished information, in 
whole or in part.
2. Design of experiments. 
• Minimal: Party 1 will not be privy to details of the intended use 
of the reagents or data, beyond those necessary to prepare the 
reagents adequately. 
• Option  1: Party 2 will describe the design of their experiments 
and invite comments from Party 1. Any suggestions that are 
implemented will be considered part of an active collaboration and 
credited appropriately. 
• Option  2: Both parties will contribute actively to the design of 
experiments, including control experiments. 
3. Division of labor. 
• Minimal: Party 1 provides reagents/expertise/equipment/data but 
does not participate in the experiments of Party 2. 
• Option  1: Party 1 provides training and specialized expertise to 
personnel of Party 2, thus facilitating the work, but does not carry out 
the research directly. 
• Option  2: Both parties participate in experiments, but each does the 
subset of experiments they are most experienced, knowledgeable, 
or comfortable with and the other group(s) do the same with 
nonoverlapping subsets of experiments. 
• Option  3: Party 1 provides assistance with personnel and training to 
help with Party 2’s experiments, forming an interlaboratory team that 
has ongoing communication during experiments and that shares the 
costs of doing the research. 
4. Publication of results stemming from the collaboration. 
• Minimal: Party 2 will acknowledge the source of the reagent or data 
in their publications, and will cite the providers’ relevant publications 
that described the reagent and its use. 
• Option  1: Party 1 will be given a copy of the manuscript prior to 
publication and given the option to be included in the list of authors, 
unless Party 1 disagrees materially with the paper, or fails to answer 
in a reasonable time frame. 
• Option  2: Both parties participate in writing the paper, and the 
resulting publication spells out the contributions of each. 
5. Co-authorship order. 
• Minimal: Party 2 will write the paper and choose the order of 
authorship that Party 2 feels is fair and appropriate. 
• Option  1: At the time that a decision is made to offer co-authorship 
to Party 1, Party 2 will discuss the planned order of authors and the 
rationale with Party 1. 
• Option  2: As the experiments are being designed and planned, both 
parties will be apprised of the relative roles of individuals in both 
laboratories, and a tentative co-author list will be discussed. Any 
changes will be discussed in advance of writing the paper.
6. Access to unpublished data arising from the collaboration. 
• Minimal: Party 1 has no right to access to any data obtained by Party 2. 
• Option  1: Party 2 will give basic feedback on how the material 
supplied by Party 1 was used. 
• Option  2: Party 2 shares the speciﬁ  c results obtained with Party 1, 
with the understanding that such information is conﬁ  dential and 
cannot be used by Party 1 without the written consent of Party 2. 
• Option  3: Party 1 has access to data originally intended for 
publication under joint authorship, whether or not the data are 
actually published. The unpublished data can be used by Party 1 in 
their grant submissions and for their own knowledge. 
• Option  4: Both parties will discuss the types of experiments that are 
being conducted in the general area of the collaboration, and will 
discuss which activities (beyond the joint experiments) should be 
shared knowledge.
7. Intellectual property issues. Negotiations of intellectual property 
issues fall beyond the scope of the present guidelines. However, potential 
collaborators should at least acknowledge the types of intellectual 
property issues that may arise in the course of the collaboration. 
• Minimal: Party 2 does not share in any intellectual property related 
to the existing reagent or data. 
• Optional: If the joint experiments or data analyses result in new 
information or uses having commercial value, both parties will 
negotiate shared intellectual property. 
Box 1. Suggested Guidelines for Negotiating Scientiﬁ  c Collaboration
The guidelines here are discussed in terms of a collaboration involving a supplier (e.g., of reagents, expertise, specialized equipment, data, methods, or 
computer code) (Party 1) and a receiver (Party 2). The options in each section are listed in order of increasing involvement by Party 1 in the collaboration. 
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